[1]李慧华,杨敏,余敏,等.β3AR Trp64Arg遗传多态性对T2DM患者罗格列酮疗效的影响[J].中国药理学通报,2009,(03):0.
 LI Hui hua,YANG Min,YU Min,et al.The effect of β3AR Trp64Arg on rosiglitazone response in T2DM patients[J].Chinese Pharmacological Bulletin,2009,(03):0.
点击复制

β3AR Trp64Arg遗传多态性对T2DM患者罗格列酮疗效的影响()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2009年03期
页码:
0
栏目:
论著
出版日期:
2009-03-25

文章信息/Info

Title:
The effect of β3AR Trp64Arg on rosiglitazone response in T2DM patients
作者:
李慧华杨敏余敏周宏灏刘昭前
中南大学临床药理研究所,遗传药理学湖南省重点实验室,湖南 长沙410078
Author(s):
LI HuihuaYANG Min YU MinZHOU HonghaoLIU Zhaoqian
Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha410078, China
关键词:
β3肾上腺素受体基因多态性2型糖尿病罗格列酮
Keywords:
β3adrenergic receptor genetic polymorphism type 2 diabetes rosiglitazone
分类号:
R 39211;R 3943;R 3942
文献标志码:
A
摘要:
目的探讨β3肾上腺素受体 (β3adrenergic receptor,β3AR) Trp64Arg基因变异在中国健康人群和2型糖尿病 (type 2 diabetes,T2DM)患者中的分布频率,查明该遗传多态性对罗格列酮在T2DM患者中疗效的影响。方法采用聚合酶链式反应-限制性片断长度多态性(polymerase chain reactionrestriction fragment length polymorphism,PCRRFLP) 对255名T2DM患者和148名健康对照者进行β3AR Trp64Arg基因型分析,并在T2DM组中随机选取34名患者每天口服4mg罗格列酮,持续12 wk。服药前和服药第12周末进行血糖、血胰岛素以及糖化血红蛋白等指标的测定。结果β3AR Trp64Arg等位基因的发生频率符合HardyWeinberg平衡,64Arg等位基因在T2DM组和健康对照组的频率分别为013和017。罗格列酮治疗12 wk后, Trp64Arg基因型患者甘油三酯的下降值低于Trp64Trp型患者(P<005),但后者对低密度脂蛋白胆固醇 (P<001)与脂联素(P<005) 的作用优于Trp64Arg基因型患者。结论β3AR Trp64Arg遗传多态性与中国汉族人群T2DM发病无明显相关性,但对2型糖尿病中罗格列酮的疗效存在一定影响。
Abstract:
AimTo explore the impact of β3adrenergic receptor (ADRB3) genetic variation on therapeutic efficacy of rosiglitazone in Chinese T2DM patients. MethodsThe genotypes of ADRB3 Trp64Arg in 255 T2DM patients and 148 healthy volunteers were determined by polymerase chain reactionrestriction fragment length polymorphism (PCRRFLP) assay. Samples were randomly selected for direct DNA sequencing to identify the results of PCRRFLP assay. 34 T2DM patients administrated orally 4 mg rosiglitazone daily for 12 consecutive weeks. The concentrations of fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, fasting serum insulin, postprandial serum insulin and so on in all T2DM subjects were determined before and after rosiglitazone treatment for 12 consecutive weeks. ResultsThere were no significant differences in the distributive frequency of the ADRB3 Trp64Arg polymorphisms between T2DM patients and controls. Our results showed that ADRB3 Trp64Arg had bigger attenuated serum triglyceride (P<005) and smaller attenuated lowdensity lipoproteincholesterol (P<001) as well as smaller enhanced adiponectin (P<005) compared with ADRB3 Trp64Atrp. ConclusionADRB3 Trp64Arg genetic polymorphism are associated with therapeutic efficacy of multipledose rosiglitazone in Chinese T2DM patients.

参考文献/References:

[1]Sun H, Gong Z C , Yin J Y, et al.The association of adiponectin allele 45T/G and11377C/G polymorphisms with type 2 diabetes and rosiglitazone response in Chinese patients[J].Br J Clin Pharmacol,2008, 65(6):917-26.
[2]Liu H L,Lin Y G, Wu J,et al. Impact of genetic polymorphisms of leptin and TNFα on rosiglitazone response in Chinese patients with type 2 diabetes[J].Eur J Clin Pharmacol, 2008,64(7):663-71.
[3]Blüher M,Lübben G,Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPARγ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes[J].Diabetes Care,2003,26(3):825-31.
[4]Grinberg A, Park A W. Nuclear peroxisom proliferator activated receptors and thiazolidinediones[J].Intern Anesthesiol Clin, 2005, 43(2):1-21.
[5]Berger J P,Akiyama T E,Meinke P T. PPARs: therapeutic targets for metabolic disease[J].Trends Pharmacol Sci,2005,26(5): 244-52.
[6]Hammarstedt A,Andersson C X,Rotter Sopasakis V,et al. The effect of PPAR gamma ligands on the adipose tissue in insulin resistance[J].Prostaglandins Leukot Essent Fatty Acids,2005,73(1):65-75.
[7]葛斌,谢梅林,顾振纶,等. AMPK作为治疗2型糖尿病新靶点的研究进展[J].中国药理学通报,2008,24(5):580-3.
[7]Ge B,Xie M L,Gu Z L,et al. AMPK acts as a new target for the treatment of type 2 diabetes[J].Chin Pharmacol Bull,2008,24(5):580-3.
[8]Kim Y M,Cha B S,Kim D J,et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2005,(1): 43-52.
[9]Kang E S,Park S Y,Kim H J,et al. Effects of Pro12Ala polymorphism of peroxisome proliferatoractivated receptor gamma2 gene on rosiglitazone response in type 2 diabetes[J].Clin Pharmacol Ther,2005,78(2):202-8.
[10]Kang E S,Park S Y,Kim H J,et al.The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes[J].Diabetes Care,2005,28(5):1139-44.
[11]Perfetti R,Hui H,Chamie K,et al. Pancreatic betacells expressing the Arg64 variant of the beta(3)adrenergic receptor exhibit abnormal insulin secretory activity[J].J Mol Endocrinol,2001,27(2):133-44.
[12]Chamberlain P D,Jennings K H,Paul F,et al. The tissue distribution of the human beta3adrenoceptor studied using a monoclonal antibody:direct evidence of the beta3adrenoceptor in human adipose tissue,atrium and skeletal muscle[J].Int J Obes Relat Metab Disord,1999,23(10):1057-65.
[13]Walston J,Silver K,Bogardus C,et al. Time of onset of noninsulindependent diabetes mellitus and genetic variation in the beta 3adrenergicreceptor gene[J].N Engl J Med,1995,333(6):343-7.
[14]Oeveren vanDybicz A M,Vonkeman H E,Bon M A,et al. Beta 3adrenergic receptor gene polymorphism and type 2 diabetes in a Caucasian population[J].Diabetes Obes Metab,2001,3(1):47-51.
[15]Kasznicki J,Blasiak J,Majsterek I,et al. The Trp64Arg beta3adrenergic receptor aminoacid variant is not associated with overweight and type 2 diabetes mellitus in Polish population[J].Exp Clin Endocrinol Diabetes,2005,113(10):593-7.
[16]Xiu L L,Weng J P,Sui Y,et al. Common variants in beta3adrenergicreceptor and uncoupling protein2 genes are associated with type 2 diabetes and obesity[J].Zhonghua Yi Xue Za Zhi,2004,84(5):375-9.
[17]Oizumi T,Daimon M,Saitoh T,et al. Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the beta(3)adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample[J].Diabetes Care,2001,24(9):1579-83.

相似文献/References:

[1]马晶晶,李金恒,曹晓梅,等.基因多态性对奥美拉唑药动学与相对生物利用度的影响[J].中国药理学通报,2010,(02):258.
 MA Jing jing,LI Jin heng,CAO Xiao mei,et al.Effects of CYP2C19 polymorphism on pharmacokinetic profile and comparative bioavailability of omeprazole[J].Chinese Pharmacological Bulletin,2010,(03):258.
[2]杨静,乔海灵.过敏反应与HLA基因多态性[J].中国药理学通报,2008,(04):0.
 YANG Jing,QIAO Hai Ling.Correlation between allergy and HLA genetic polymorphism[J].Chinese Pharmacological Bulletin,2008,(03):0.
[3]杨静,乔海灵.青霉素特异性IgE抗体的种类与HLADRB基因多态性[J].中国药理学通报,2008,(06):0.
 YANG Jing,QIAO Hai ling.Correlation of HLADRB genetic locus with penicillinspecific IgE antibodies[J].Chinese Pharmacological Bulletin,2008,(03):0.
[4]陈豪,谭志荣,周宏灏.含黄素单氧化酶3(FMO3)结构、功能及其基因多态性的研究进展[J].中国药理学通报,2008,(10):0.
 CHEN Hao,TAN Zhi rong,ZHOU Hong hao.Advance in flavincontaining monooxygenase 3 (FMO3):structure/function and genetic polymorphisms[J].Chinese Pharmacological Bulletin,2008,(03):0.
[5]余敏,周宏灏,刘昭前.糖尿病肾病相关基因研究进展[J].中国药理学通报,2008,(11):0.
 YU Min,ZHOU Hong hao,LIU Zhao qian.Progress in related genes of diabetic nephropathy[J].Chinese Pharmacological Bulletin,2008,(03):0.
[6]吴培培,李奕,杨飞,等.抗癫痫药物等引发药疹与人类白细胞抗原基因的相关性研究[J].中国药理学通报,2013,(01):113.
 WU Pei pei,LI Yi,YANG Fei,et al.Druginduced cADR and polymorphism of HLA genes:A correlational study[J].Chinese Pharmacological Bulletin,2013,(03):113.
[7]彭娟,谭胜蓝,周宏灏,等.华法林药物基因组学和个体化用药[J].中国药理学通报,2013,(02):169.
 PENG Juan,TAN Sheng lan,ZHOU Hong Hao,et al.Pharmacogenomics of warfarin and its personalized treatment[J].Chinese Pharmacological Bulletin,2013,(03):169.
[8]李璐,王明霞,赵宝华.细胞色素P450 2D6、3A4和19A1基因多态性与乳腺癌的药物治疗[J].中国药理学通报,2013,(03):311.
 LI Lu,WANG Ming xia,ZHAO Bao hua.Cytochrome P450 2D6, 3A4 and 19A1:gene polymorphism and drug therapy of breast cancer[J].Chinese Pharmacological Bulletin,2013,(03):311.
[9]邵倩,班博,施锦绣.SUR1和KCNJ11基因多态性与磺脲类药物继发性失效的相关性研究[J].中国药理学通报,2013,(07):927.
 SHAO Qian,BAN Bo,SHI Jin xiu.Relations of SUR1 and KCNJ11 gene polymorphisms with secondary failure of sulfonylurea in type 2 diabetes[J].Chinese Pharmacological Bulletin,2013,(03):927.
[10]李江峰,闫良,王晓飞,等.高脂饮食及ABCB1基因多态性对硝苯地平 在健康受试者体内药动学的影响[J].中国药理学通报,2014,(04):566.
 LI Jiang-feng,YAN Liang,WANG Xiao-fei,et al.Effect of high-fat meal and ABCB1 C3435T polymorphism onpharmacokinetics of nifedipine in healthy Chinese subjects[J].Chinese Pharmacological Bulletin,2014,(03):566.

备注/Memo

备注/Memo:
收稿日期:2008-11-05,修回日期:2009-01-08基金项目:国家自然科学基金资助项目(No 30572230);湖南省自然科学基金重点资助项目(No 08JJ3058 );湖南省“芙蓉学者计划”特聘教授基金资助项目(No湘教通[2006]312号)作者简介:李慧华 (1979-),男,博士生,研究方向:遗传药理学,Tel: 07314805380, Email: lihuihua007@yahoo.com.cn;刘昭前(1963-),男,博士,教授,博士生导师,研究方向:遗传药理学, 通讯作者,Tel/Fax: 07314805380, Email: liuzhaoqian63@126.com
更新日期/Last Update: 2009-03-25